why choose us

First received: March 23, 2023

Clinical Trial: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Study Status: Completed

Recruit Status: RECRUITING

Condition: NSCLC

Study Type: INTERVENTIONAL


Official Title: Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC

Brief Summary: This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.

Read more